Bronchodilator Therapy of Airway Diseases

Pharmacology and Therapeutics of Airway Disease: Second Edition

Volumn , Issue , 2009, Pages 198-225

  Donohue, James F ^a   Ohar, Jill ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903615631     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420070019-10     Document Type: Chapter

References (149)

1. Taylor DR, Bateman E, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-554.
2. Barnes PJ. Airway Pharmacology. 4th ed. Philadelphia: Saunders, 2005.
3. Guidelines for the diagnosis and management of asthma 2007. Available at: http://nhlbi.nih. gov/guidelines/asthma/asthgdln.pdf. Accessed March 12, 2008, 2008.
4. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
5. Papi A. Treatment strategies in mild asthma. Curr Opin Pulm Med 2009; 15:290-234.
6. American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-2039.
7. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040-2052.
8. Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med Clin North Am 1996; 80:719-748.
9. Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging 2008; 25:415-443.
10. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols:a review. Prev Med 1978; 7:519-538.
11. Keating G, Mitchell EA, Jackson R, et al. Trends in sales of drugs for asthma in new zealand, australia and the united kingdom. Br Med J (Clin Res Ed) 1984; 289:348-351.
12. Hancox RJ. Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis. Clin Rev Allergy Immunol 2006; 31:279-288.
13. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105:883-890.
14. Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet 1995; 345:41-44.
15. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48:134-138.
16. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841-847.
17. Larj MJ, Bleecker ER. Pharmacogenetics of asthma: where are we now? Clin Chest Med 2006; 27:109-117, vii.
18. Taylor DR. Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy Immunol 2006; 31:247-258.
19. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)- adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
20. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762-767.
21. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
22. Barnes PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am J Respir Crit Care Med 2006; 174:969-972; discussion 72-74.
23. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943-952.
24. Donohue JF, Hanania NA, Ciubotaru RL, et al. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther 2008; 30 Spec No:989-1002.
25. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155:291-299.
26. Walters EH, Gibson PG, Lasserson TJ, et al. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007:CD001385.
27. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy:results of a meta-analysis. Respir Res 2006; 7:147.
28. Salpeter SR. Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2007; 2:11-18.
29. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen and Hanburys Limited UK Study Group. Lancet 1994; 344:219-224.
30. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev 2005:CD005307.
31. O’Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest 2008; 134:1192-1199.
32. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009.
33. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836-844.
34. Bateman ED, Bousquet J, Busse WW, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008; 63:932-938.
35. O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136.
36. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037.
37. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
38. Jaeschke R, O’Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178:1009-1016.
39. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting betaagonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
40. Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006; 145:692-694.
41. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33-42.
42. FDA public health advisory.Severvent diskus (salmeterol xinafoate inhalation powder), Advair diskus (fluticasone propionate and salmeterol inhalation powder), Foradil aerolizer (formoterol fumarste inhalation powder). 2006. Available at: http://www.fda.gov/cder/drug/advisory/laba.htm. Accessed March 14, 2008, 2006.
43. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
44. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebocontrolled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86:19-27.
45. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002; 89:180-190.
46. Wolfe J, Laforce C, Friedman B, et al. Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129:27-38.
47. Sears MR, Ottosson A, Radner F, et al. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21-32.
48. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 2009; 360:1592-1595.
49. Drazen JM, O’Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009; 360:1671-1672.
50. Sears MR. Safety of Long-Acting Beta-Agonists: Are New Data Really Required? Chest 2009; 136 (2):604-607.
51. Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
52. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-2125.
53. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2- adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816.
54. Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009; 33:1010-1017.
55. Momeni A, Mohammadi MH. Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma. J Microencapsul 2009:1-10.
56. Adachi M, Aizawa H, Ishihara K, et al. Comparison of salmeterol/fluticasone propionate (FP) combination with FPþsustained release theophylline in moderate asthma patients. Respir Med 2008; 102:1055-1064.
57. Suissa S, Dell’Aniello S, Ernst P. Effectiveness of combination therapies in asthma: an observational study. Pulm Pharmacol Ther 2009; 22:194-198.
58. O’Byrne PM, Adelroth E. Beta2 deja vu. Chest 2006; 129:3-5.
59. Fabbri L, Pauwels RA, Hurd SS, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. COPD 2004; 1:105-141; discussion 3-4.
60. Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators Chest 2004; 126:(2 suppl):125S-137S.
61. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664.
62. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
63. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14:775-783.
64. Hanania NA, Sharafkhaneh A, Barber R, et al. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002; 165:1353-1358.
65. Lotvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 2000; 94(suppl E):S6-S10.
66. Sestini P, Renzoni E, Robinson S, et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002:CD001495.
67. Ramirez-Venegas A, Ward J, Lentine T, et al. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336-340.
68. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10:815-821.
69. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89:357-362.
70. Hanania NA, Kalberg C, Yates J, et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005; 18:19-22.
71. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965.
72. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784.
73. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3:CD006101.
74. Cazzola M, Santus P, Matera MG, et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 2003; 97:458-462.
75. Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100:1925-1932.
76. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respir Med 2008; 102:173-188.
77. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99:1511-1520.
78. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73:414-419.
79. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290:2301-2312.
80. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008; 133:1079-1087.
81. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61:122-128.
82. Costello J. Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol. J Allergy Clin Immunol 1999; 104:S61-S68.
83. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123:128-135.
84. Arformoterol: (R, R)-eformoterol, (R, R)-formoterol, arformoterol tartrate, eformoterolsepracor, formoterol-sepracor, R, R-eformoterol, R, R-formoterol. Drugs R D 2004; 5:25-27.
85. Steinke JW, Baramki D, Borish L. Opposing actions of (R, R)-isomers and (S, S)-isomers of formoterol on T-cell function. J Allergy Clin Immunol 2006; 118:963-965.
86. Ameredes BT, Calhoun WJ. (R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma:con]. Am J Respir Crit Care Med 2006; 174:965-969; discussion 72-74.
87. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007; 29:261-278.
88. Johnson M, Rennard S. Alternative mechanisms for long acting beta (2)-adrenergics agonists in COPD. Chest 2001; 120:258-270.
89. Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy 2004; 3:271-277.
90. Bennett WD, Almond MA, Zeman KL, et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther 2006; 19:96-100.
91. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989; 96:984-987.
92. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311:421-425.
93. O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine- induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154:876-880.
94. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542-549.
95. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001; 17:1132-1137.
96. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224.
97. O’Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86-94.
98. Anzueto A, Tashkin D, Menjoge S, et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18:75-81.
99. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002; 19:209-216.
100. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317-326.
101. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
102. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once-daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404.
103. Briggs DD Jr., Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18:397-404.
104. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61:854-862.
105. Tashkin DP, Celli B, Senn S. A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
106. Gershon AS, Wang L, To T, et al. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease. COPD 2008; 5:229-234.
107. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:297-304; discussion 11-12.
108. Profita M, Giorgi RD, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005; 60:1361-1369.
109. Barnes PJ. Theophylline for COPD. Thorax 2006; 61:742-744.
110. Cazzola M, Gabriella Matera M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101:957-962.
111. Man GC, Champman KR, Ali SH, et al. Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Chest 1996; 110:648-653.
112. Cyr MC, Beauchesne MF, Lemiere C, et al. Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 2008; 65:40-50.
113. Hanania NA, Ambrosino N, Calverley P, et al. Treatments for COPD. Respir Med 2005; 99(suppl B):S28-S40.
114. Barnes PJ. Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin Ther Targets 2005; 9:1111-1121.
115. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2:334-339; discussion 40-41.
116. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818.
117. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit CareMed 2006; 173:736-743.
118. Johnson M. Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:200-206.
119. Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:320-325; discussion 40-41.
120. Sin DD, Johnson M, Gan WQ, et al. Combination therapy of inhaled corticosteroids and long-acting beta2-adrenergics in management of patients with chronic obstructive pulmonary disease. Curr Pharm Des 2004; 10:3547-3560.
121. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843.
122. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
123. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456.
124. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
125. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnisis, management and prevention of chronic obstrictive pulmonary disease. 2004. Available at:http://www.goldcopd.org. Accessed 4-24-2005, 2005.
126. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005; 2:272-281; discussion 90-91.
127. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411-1419.
128. D’Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119:1347-1356.
129. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-885.
130. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661-1670.
131. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17:35-39.
132. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214-222.
133. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509-517.
134. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102:479-487.
135. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6:17-25.
136. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255-262.
137. Perng DW, Wu CC, Su KC, et al. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006; 11:598-602.
138. Singh D, Brooks J, Hagan G, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63:592-598.
139. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease:a randomized trial. Ann Intern Med 2007; 146:545-555.
140. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21:405-414.
141. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21:1011-1019.
142. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
143. Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817-1824.
144. Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol:results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008; 2:199-208.
145. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65:1595-1610.
146. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97:1014-1020.
147. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439-1450.
148. Barnes PJ. Current therapies for asthma. Promise and limitations. Chest 1997; 111:17S-26S.
149. Charytan D, Jansen K. Severe metabolic complications from theophylline intoxication. Nephrology (Carlton) 2003; 8:239-242.